InSite Vision Announces FDA Approval Of New Ophthalmic Product Enabled By InSite's DuraSite Technology (Medical News Today)
InSite Vision Incorporated (OTCBB:INSV) announced that Bausch & Lomb has received approval of Besivance (besifloxacin ophthalmic suspension) 0.6% for the treatment of bacterial conjunctivitis ("pink eye") in patients one year and older from the U.S. Food and Drug Administration (FDA).

Advanced Life Sciences Announces Outcome Of FDA's Anti-Infective Drugs Advisory Committee Review Of Restanza(TM) ... (Medical News Today)
Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced that the FDA's Anti-Infective Drugs Advisory Committee voted in the majority that Restanza(TM) (cethromycin) demonstrated safety for the outpatient treatment of adults with mild-to-moderate community acquired pneumonia (CAP) (11 positive, 3 negative, 1 abstaining).